N-H ketoimines 3a-3v are readily prepared in high yield via organometallic addition to nitrites and isolated as corresponding bench-stable hydrochloride salts. Homogeneous asymmetric hydrogenation of unprotected N-H ketoimines 3a-3v using Ir-(S,S)-f binaphane as catalyst provides chiral amines 4a-4v in 90-95% yield with enantioselectivities up to 95% ee.
BENZIMIDAZOLE DERIVATIVES AND USE THEREOF AS IDH1 INHIBITORS
申请人:KPC Pharmaceuticals, Inc.
公开号:EP3816158A1
公开(公告)日:2021-05-05
The present invention relates to benzimidazole compounds and an application thereof as IDH1 mutant inhibitors, in particular, to a compound as represented by formula (I), tautomers thereof, or pharmaceutically acceptable salts thereof.
Benzimidazole derivatives and use thereof as IDH1 inhibitors
申请人:KPC PHARMACEUTICALS, INC.
公开号:US11407717B2
公开(公告)日:2022-08-09
The present invention relates to benzimidazole compounds and an application thereof as IDH1 mutant inhibitors, in particular, to a compound as represented by formula (I), tautomers thereof, or pharmaceutically acceptable salts thereof.
作者:Guohua Hou、Francis Gosselin、Wei Li、J. Christopher McWilliams、Yongkui Sun、Mark Weisel、Paul D. O’Shea、Cheng-yi Chen、Ian W. Davies、Xumu Zhang
DOI:10.1021/ja903319r
日期:2009.7.29
N-H ketoimines 3a-3v are readily prepared in high yield via organometallic addition to nitrites and isolated as corresponding bench-stable hydrochloride salts. Homogeneous asymmetric hydrogenation of unprotected N-H ketoimines 3a-3v using Ir-(S,S)-f binaphane as catalyst provides chiral amines 4a-4v in 90-95% yield with enantioselectivities up to 95% ee.